Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-11-05
2010-10-12
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S237800
Reexamination Certificate
active
07812023
ABSTRACT:
The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.
REFERENCES:
patent: 5688792 (1997-11-01), Barbachyn et al.
patent: 2001/0049444 (2001-12-01), McNaughton-Smith
patent: 03175086 (1991-07-01), None
patent: WO 02/49628 (2002-06-01), None
patent: WO 02/66036 (2002-08-01), None
Main, M. J. et al., “Modulation of KCNQ2/3 Potassium Channels by the Novel Anticonvulsant Retigabine” Molecular Pharmacology, Baltimore, MD, USA, vol. 58, No. 2, Aug. 2000, pp. 253-262.
Database Beilstein Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE, BRN 6233316 1993, XP002330358 abstract & Verma M AL: Arch Pharm (Weinheim W Ger), vol. 315, No. 7, 1962, pp. 356-363.
Khanzhin Nikolay
Ritzen Andreas
Rottländer Mario
Tornøe Christian Wenzel
Watson William Patrick
H. Lundbeck A/S
Habte Kahsay T
LandOfFree
Methods of using substituted morpholine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using substituted morpholine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using substituted morpholine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228961